John Overdeck’s Processa Pharmaceuticals PCSA Stock Holding History

John Overdeck’s Portfolio PCSA Stock Details PCSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-964	Closed	-$57K	–	3250
2024 Q1	$57K	Buy	964 +927	+2,505%	+$73.4K	﹤0.01%	2877
2023 Q4	$6.25K	Buy	+37	New	+$8.26K	﹤0.01%	3098

Other funds holding PCSA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

MSG

Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return

Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

MIM

Macroview Investment Management Bethesda, Maryland $162M AUM 22.52% 1-Year Est. Return

John Overdeck's PCSA Position: Q2 2024 in Review

John Overdeck sold out of Processa Pharmaceuticals (PCSA) in Q2 2024, closing a stake of 964 shares — an estimated $57K sold.

John Overdeck first reported a position in PCSA in Q4 2023 and held it in 2 quarters. The position peaked at $57K in Q1 2024. 7 funds tracked by Wall St. Rank hold PCSA as of Q2 2024.

John Overdeck reported no remaining Processa Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
John Overdeck sold 964 Processa Pharmaceuticals shares in Q2 2024, an estimated $57K.
John Overdeck first reported a position in Processa Pharmaceuticals in Q4 2023 and held it in 2 quarters.
John Overdeck's Processa Pharmaceuticals position peaked at $57K in Q1 2024.
7 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q2 2024.

Based on Two Sigma Investments's 13F filing for Q2 2024, filed 14 Aug 2024.